| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Navoximod (formerly known as IDO-IN-7; NLG-1488; NLG919) is a potent inhibitor of the IDO (indoleamine-(2,3)-dioxygenase) pathway (Ki/EC50 = 7 nM/75 nM) with potential immunomodulating and antineoplastic activities. Navoximod was obtained by rational structural design based on the X-ray crystal structure for IDO complexed with 4-phenyl-imidazole (PIM). It is a strong competitive IDO inhibitor and potently inhibits IDO pathway in vitro and in cellular assays. In Phase Ia clinical trial for the treatment of advanced-stage solid tumors, Navoximod demonstrated the high dose tolerance (well tolerated up to 800 mg BID on a 21/28 day cycle), but revealed that single-agent therapy with an IDO inhibitor failed to cause tumor eradication and to prevent disease progression (best response was limited to stable disease in 7 out of 17 patients). Navoximod is now being evaluated in phase Ib in combination with PD-L1 inhibitor atezolizumab.
| ln Vitro |
Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, Navoximod abrogates IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with an ED50=120 nM[1]. Using IDO-expressing human monocyte-derived dendritic cells (DCs) in allogeneic mixed lymphocyte reaction (MLR) reactions, Navoximod (NLG919) potently blocks IDO-induced T cell suppression and restores robust T cell responses with an ED50=80 nM. With an EC50 of 0.95 μM, navoximod suppresses IDO activity in a concentration-dependent manner. When compared to free Navoximod, PEG2k-Fmoc-NLG(L) exhibits a lower EC50 of 3.4 μM for IDO inhibition, but PEG2k-Fmoc-NLG(S) exhibits the lowest EC50 of >10 μM. The coculture of IDO+tumor cells with BALB/c mouse splenocytes results in a notable suppression of T-cell proliferation. When Navoximod is administered to the mixed cells, this inhibition is greatly reduced. Though marginally less effective than Navoximod, PEG2k-Fmoc-NLG(L) is likewise active in reversing the inhibitory effect of tumor cells [3].
|
||
|---|---|---|---|
| ln Vivo |
Orally bioavailable (F>70%), vNavoximod (NLG919) has a good pharmacokinetic and toxicological profile. A single oral dose of navoximod in mice lowers tissue Kyn and plasma concentrations by approximately 50%. Navoximod treatment significantly increases the anti-tumor responses of naïve, resting pmel-1 cells following immunization with homologous hgp100 peptide plus CpG-1826 in IFA in vivo in mice carrying large developed B16F10 tumors. When compared to control mice who received pmel-1/vaccine alone without Navoximod, Navoximod plus pmel-1/vaccine resulted in a significant collapse of tumor growth within 4 days of immunization (~95% reduction in tumor volume)[1]. Compared to mice treated with NSC 362856 (TMZ)+RT alone, both Navoximod and D-1MT (Indoximod) improve survival when paired with these treatments[2].
|
||
| Animal Protocol |
|
||
| References |
[1]. Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.
[2]. Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. [3]. Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443 |
| Molecular Formula |
C18H21FN2O2
|
|
|---|---|---|
| Molecular Weight |
316.38
|
|
| CAS # |
1402837-78-8
|
|
| Related CAS # |
IDO-IN-5;1402837-79-9;IDO-IN-6;1402837-76-6;IDO-IN-8;1402837-77-7
|
|
| SMILES |
O[C@@H]([ C@H]1CC[ C@H](O)CC1)C[C@@H](C2=C3C=CC=C2F)N4C3=CN=C4
|
|
| Chemical Name |
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 0.5 mg/mL (1.58 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1608 mL | 15.8038 mL | 31.6076 mL | |
| 5 mM | 0.6322 mL | 3.1608 mL | 6.3215 mL | |
| 10 mM | 0.3161 mL | 1.5804 mL | 3.1608 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Figure 1n vitrobiological activities of PEG2k-Fmoc-NLG.Nat Commun. 2016 Nov 7;7:13443. |
|---|
 In vivobiological activities of PEG2k-Fmoc-NLG.Nat Commun. 2016 Nov 7;7:13443. |
 IDO-blockade synergizes with chemo-radiation therapy. |
 Inhibition or absence of IDO triggers widespread complement deposition in tumors after chemo-radiation therapy.J Immunother Cancer. 2014 Jul 7;2:21. |
|---|
 Dose-dependent antitumor efficacy ofNLG919.Int J Immunopathol Pharmacol.2017 Sep;30(3):215-226. |
 Combinatorial treatment withNLG919and paclitaxel.J Immunother Cancer. 2014 Jul 7;2:21.
NLG919increased the sensitivity of B16-F10 cells to paclitaxel after treatment with IFN-γ.Int J Immunopathol Pharmacol.2017 Sep;30(3):215-226. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
